CDKL2 and central nervous system cancer: However, in gliomas, hepatocellular carcinoma, and gastric cancer, its underexpression or hypermethylation of its promoter indicates poor prognosis of patients; additionally, overexpression of CDKL2 in gastric cancer cells suppresses the growth and invasion of cancer cells [36–38].